Exchange Traded Concepts, LLC Genmab A/S Transaction History

Exchange Traded Concepts, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Apr 17, 2025	SELL	$18.69 - $24.14 $3,289 - $4,248	-176 Reduced 2.79%	6,124 $119,000
Q3 2024 Oct 10, 2024	SELL	$23.84 - $28.48 $20,836 - $24,891	-874 Reduced 12.18%	6,300 $153,000
Q2 2024 Aug 13, 2024	SELL	$25.13 - $30.27 $56,039 - $67,502	-2,230 Reduced 23.71%	7,174 $180,000
Q1 2024 Apr 15, 2024	BUY	$26.43 - $32.77 $150,994 - $187,215	5,713 Added 154.78%	9,404 $281,000
Q4 2023 Jan 05, 2024	BUY	$27.94 - $35.44 $26,151 - $33,171	936 Added 33.97%	3,691 $117,000

Q3 2023 Oct 18, 2023	SELL	$35.27 - $42.24 $33,189 - $39,747	-941 Reduced 25.46%	2,755 $97,000
Q2 2023 Jul 20, 2023	BUY	$37.4 - $42.94 $138,230 - $158,706	3,696 New	3,696 $140,000

275

62.7M

58.8K

10.2K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $19.9B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Exchange Traded Concepts, LLC, based on Form 13F filings with the SEC.

Stay updated on Exchange Traded Concepts, LLC with notifications on news.